A combination of casirivimab and imdevimab, a monoclonal antibody cocktail developed by Regeneron, is recommended for:Patients with confirmed non-severe COVID-19 at highest risk for hospitalization. Those at highest risk are typically individuals older than 60, have a chronic disease, are immunocompromised, or are not vaccinated. Patients with severe or critical COVID-19* who do not have antibodies to the COVID-19 virus    (i.e., those who are seronegative).This drug should be administered by a healthcare worker in a monitored clinical setting along with the current standard of care for COVID-19 which may include oxygen and other medications.  *A patient has severe COVID-19 when they have signs of pneumonia, severe respiratory distress, and their blood oxygen level is low. A patient has critical COVID-19 when they need life sustaining treatment, have acute respiratory distress syndrome, or have septic shock (evidence of injury to other organs ). More.
